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Abstract
Aims The aim of this study was to use general practice data to estimate the prevalence of diabetic nephropathy within the
registered diabetes patients and examine variation in practice prevalence and management performance since introduction of
this initiative.
Methods Reported quality indicators from the Northern Ireland General Practice Quality and Outcomes Framework were
analysed for diabetes and diabetic nephropathy prevalence and management in the period 2004–2008. Variation in prevalence
at practice level was assessed using multiple linear regression adjusting for age, practice size, deprivation and glycaemic
control.
Results In 2006–2007, 57 454 (4.1%) adult diabetic patients were registered in the denominator population of 1.4 million
compared with 51 923 (3.8%) in 2004–2005 (mean practice range 0.5–7.7%). Diabetic nephropathy prevalence was 15.1 and
11.5%, respectively (8688 and 5955 patients). Documented diabetic nephropathy prevalence showed marked variation across
practices (range 0–100%) and was significantly negatively correlated with diabetes list size, albumin creatinine ratio testing rates
and renin–angiotensin–aldosterone system blockade use and positively correlated with exception reporting rates. Specifically,
for every increase in 100 diabetic patients to a register, documented diabetic nephropathy prevalence reduced by 40%
(P = 0.003). On the positive side, median albumin-creatinine ratio testing rates doubled to 82% compared with figures in the
pre-Framework era.
Conclusions Implementation of the Northern Ireland General Practice Quality and Outcomes Framework has positively
benefitted testing for diabetic nephropathy and increased numbers of detected patients in a short space of time. Large variation in
diabetic nephropathy prevalence remains and is associated with diabetes registry size, screening and treatment practices,
suggesting that understanding this variation may help detect and better manage diabetic nephropathy.
Diabet. Med. 27, 1372–1378 (2010)
Keywords albumin–creatinine ratio, chronic kidney disease screening, diabetic nephropathy, general practice,
prevalence
Abbreviation QOF, Quality and Outcomes Framework
Introduction
The estimated prevalence of diabetic nephropathy is influenced
by the precise age group studied, ethnicity and the force of
co-morbidity and competing causes of death. A European
cross-sectional study of Type 2 diabetic subjects calculated a
prevalence of incipient nephropathy (microalbuminuria) of 27%
and an additional 14% with overt nephropathy [1]. The
National Health and Nutrition Examination Survey
(NHANES) survey, a US population-based study of 14 000
randomly surveyed adults, documented an overall prevalence of
28.1 and 6.1% for incipient and overt nephropathy, respectively
[2]. UK population-based studies have recognized lower
prevalence rates for incipient and overt nephropathy at 19 and
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6.8%, respectively [3,4]. A more recent European study
demonstrated reductions in prevalence rates since the 1980s,
with improved diabetes and hypertension management [5].
The Quality and Outcomes Framework (QOF) is a pay-for-
performance system for general practitioners and has established
practice registers for each chronic disease rewarded (see also
Supporting Information, Appendix S1 and Roland [6]). The aim
of this study was to use QOF statistics to estimate the regional
and the practice-based prevalence for diabetes and diabetic
nephropathy for Northern Ireland. Furthermore, to examine
differences in practice diabetic nephropathy prevalence using
albumin-creatinine ratio testing rates, coexisting renin–
angiotensin–aldosterone system blockade uptake, practice
characteristics and exception reporting—any or all of which
may be related to a practice’s approach to screening and
managing diabetic nephropathy patients.
Subjects and methods
The crude diabetes-prevalence was calculated using the
proportion of patients within each diabetes register to those in
the practice list size. Only patients ‡ 17 years are included in the
QOFdiabetes registers. Therefore, the list size for eachpractice at
the end of each financial year was initially corrected to include
only those ‡ 17 years—giving more precise adult diabetes
practice prevalence (Fig. 1).
Diabetic nephropathy has been defined in stages from
microalbuminuria (also called incipient nephropathy) through
to proteinuria (overt) in both Type 1 and Type 2 diabetic
patients [7,8]. General practices use the national guidance
[National Institute for Health and Clinical Excellence (NICE)
and Scottish Intercollegiate Guidelines Network (SIGN)], which
define diabetic nephropathy with an albumin-creatinine ratio
> 2.5 mg ⁄mmol in men and > 3.5 mg ⁄mmol in women (the
combination of incipient and overt nephropathy) [9–11].
This was taken from the denominator in QOF indicator 15
in the diabetes domain after re-inclusion of exception-
reported patient numbers (see also Supporting Information,
Appendix S1). Diabetic nephropathy prevalence was calculated
proportional to thediabetes registry size.Allprevalence estimates
were calculated annually in financial years, in keeping with QOF
recording.
Variation in prevalence rates were analysed for the2005–2006
financial year—being the first year that exception-reporting
statistics were available [12]. To protect patient identity, QOF
results are not published for practices which have < 5 patients in
any group. Published exception reporting enables calculation of
actual numbers with recorded nephropathy; however, this was
not possible in the first year (2004–2005) so, for the first year,
practices with less than 5 patients in the diabetes 15 denominator
were not included (116 practices).
Variables
Previously, practices in highly deprived areas and with more
diverse ethnicity had greater difficulty in achieving points in the
QOF [13]. Also, subjects from Afro-Caribbean and Indo-Asian
decent have a significantly greater risk of progressive diabetic
nephropathy than Caucasians, despite achieving equivalent
diabetes targets [14]. Northern Ireland has little ethnic diversity
when compared with the rest of the United Kingdom. The 2001
census showed that 99.2% of the population are Caucasian, with
the remaining < 1% being from ethnic minority groups—the
largest of these being Chinese (0.25%) [15]. Variation in
prevalence of diabetic nephropathy is likely therefore to be
related to organization and standards of care.
QOF statistics                 
(364 practices) 
Centralized general practice 
statistics 
 Practice list size               
(4381, IQR 2799–6753)* 
Diabetes patients        
(diabetes registry) 
(132, IQR 88–200)* 
Diabetic nephropathy (DM 15 
denominator + exceptions) 
(14, IQR 6–30)*  
Population ≥ 17 years      
(1.396 million) 
List size ≥ 17 years        
(3310, IQR 2231–5277)* 
Registered population     
(1.796 million) 
Diabetes prevalence (corrected 
for registry age) 
Diabetic nephropathy 
prevalence 
FIGURE 1 Data flow for prevalence calculations. *Practice median + interquartile range (IQR). QOF, Quality and Outcomes Framework.
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Health is closely related to income in developed societies [16].
At practice level, an income score—as a marker of material
deprivation of the population served, was calculated for
comparison between practices. Northern Ireland is divided into
5022 electoral output areas averaging 150 households. It is
recognized that the patient list of each practice would cross the
boundaries of different output areas, so using the postcode of
where the practice itself is located may underestimate markers of
deprivation and ill health [17]. Thus, a weighted mean income
score for each practice population using patient level data was
calculated. Counts of individuals living in each output area, in
age bands per practice, were multiplied by that output area’s
specific income score. Household income statistics were acquired
from the Department of Health and Personal Social Services [18].
Differences in practice prevalence rates were assessed
regarding practice characteristics, testing rates and aspects of
disease management. Other variables included were: QOF
income per practice (expressed as a proportion of total list
size)—a marker of the practice’s overall QOF achievement and
taken as reflecting organizational ability. Also included were
diabetes register size and QOF achievement in all diabetes
indicators for each practice. Other factors more specific to
diabetic nephropathy were the practices’ albumin-creatinine
ratio testing rates in diabetes, and uptake of renin-angiotensin-
aldosterone system blockade in microalbuminuria or proteinuria
and their associated exception reporting rates. Ethical approval
was granted from the Office for Research and Ethics Committee,
Northern Ireland (ORECNI) (reference: 07 ⁄NIR02 ⁄73).
Statistical analyses
Practice diabetes prevalence results were normally distributed
and expressed as mean and standard deviation. Because
distribution was skewed, the geometric mean was used to
summarize the prevalence of diabetic nephropathy at practice
level.
Data were summarized at practice level prior to further
analysis [19]. The prevalence of diabetic nephropathy at practice
level was compared between categories of practice level
characteristics using the Kruskal–Wallis test. Spearman’s
correlation coefficient was calculated to measure the
correlation between the prevalence of diabetic nephropathy
and other continuous practice level characteristics. Multiple
linear regression (log of diabetic nephropathy prevalence as
outcome) was used to compare the prevalence of diabetic
nephropathy at practice level between categories of practice level
characteristics after adjustment for potential confounders (such
as list size and income score). The list size proportion above age
65 years was used toadjust forage; likewise theproportionof the
practice’s diabetic patients with HbA1c < 7.4% (57 mmol ⁄mol)
(i.e. the highest achievement rewarded in QOF) was used to
adjust for glycaemia control. The coefficients from this model
were presented as the adjusted ratio of geometric means in one
category of practice level characteristics compared with another
[20]. QOF results for the year 2005–2006 were used for diabetic
nephropathy prevalence calculations. SPSS version 15.0 was
used for all statistical analyses (SPSS Inc., Chicago, IL, USA).
Results
Prevalence calculations for 2004–2008 for diabetes and diabetic
nephropathy are demonstrated in Fig. 2 and in the Supporting
Information (Appendix S1). In 2004–2005, 5955 diabetes
patients were recorded as having diabetic nephropathy (11.5%
of prevalent diabetes mellitus patients). This figure increased to
9213 patients in 2007–2008 (15.1% of prevalent diabetes
mellitus patients). This represents an absolute 55% increase in
diabetes patients noted to have diabetic nephropathy during the
period; 35% in the first year of the diabetes QOF.
Prevalence of diabetic nephropathy varied greatly across
practices in Northern Ireland. The median practice prevalence
of diabetic nephropathy calculated from the QOF diabetic
2004–2005 2005–2006 2006–2007 2007–2008
Population 11.47 14.58 15.12 15.07
Median practice 13.02 10.89 11.63 11.67
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FIGURE 2 Diabetic nephropathy prevalence calculations (in financial years 2004–2008). Median practice diabetes prevalence (diabetes mellitus ⁄ list
> 17 years) (corrected denominator for age in diabetes registries) ( ); Northern Ireland population diabetic nephropathy prevalence (Northern Ireland
diabetic nephropathy ⁄Northern Ireland diabetes mellitus) ( ); median general practice diabetic nephropathy prevalence ( ).
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population in the first year was 13.0% (interquartile range 7.0–
22.1). In this year, exception-reporting statistics are not
available, so these have not been included in calculations. In
the following years, median practice diabetic nephropathy
prevalence results were 10.9 (interquartile range 4.1–21.1) and
11.6 (interquartile range 4.9–22.4)%, respectively. Results for
2004–2005areartificiallyhigher, asamedianresult is taken from
only included practices with numbers of nephropathy patients
greater than 5.
Median practice diabetic nephropathy prevalence correlated
negatively with diabetes registry size (r = –0.11, P = 0.04)
(Table 1). This relationship between larger diabetes practice
size and recorded prevalence became stronger after adjusting for
confounding factors, such that for every increase in 100 diabetic
patients to the practice register, the mean prevalence of diabetic
nephropathy was reduced by 40% (P = 0.003).
Overall achievement in the QOF indicators was high, with
most practices achieving maximal points in the diabetes domain.
Median diabetes achievement was 99.9%, with the lowest
recorded achievement being 65%. There was no relationship
between diabetic nephropathy prevalence and overall diabetes
QOF attainment or with total QOF income generated.
Albumin–creatinine ratio testing rates were high at 82%, with
a significant negative correlation between increasing testing rates
and diabetic nephropathy prevalence (r = –0.18, P = 0.001)
(Table 2). The prevalence also increased significantly in practices
where the testing rate was below 70% (P < 0.01), i.e. the
maximum payment threshold. The overall trend was a reduction
in diabetic nephropathy prevalence of 20% for every 10%
increase in albumin-creatinine ratio testing rate (P £ 0.01).
Median uptake of renin-angiotensin-aldosterone system
blockade in diabetic nephropathy was 85%—across all the
practices (Table 2).
It was considered that ‘excepting’ patients from nephropathy
testing and treatment may explain the differing rates of
nephropathy found at a practice level. In 2005–2006, the
median Northern Ireland exception rates for albumin-creatinine
ratio testing and renin-anggiotensin-aldosterone system uptakes
in diabetes were 4.3 and 8.3%, respectively, with the majority of
practices not exception reporting in these indicators. There was
no correlation between median diabetic nephropathy prevalence
and increasing tertiles of albumin-creatinine ratio testing
exception rate. However, a non-linear trend was found
between prevalence and exception reporting for renin-
angiotensin-aldosterone system blockade use (Table 2), where
there was minimal exception reporting. In most practices,
253 ⁄364, this was < 5%.
Discussion
The major findings of this prevalence study, which exploits the
Quality Outcomes Framework statistics in Northern Ireland,
Table 1 The association between practice level characteristics and diabetic nephropathy prevalence
Practice characteristic
Number of
practices
Median prevalence
DN (IQR) P
Adjusted ratio of
mean prevalence (95% CI) P
Diabetic patients
< 100 112 12.5 (19.5) 1.0 (ref. cat.)
100–200 162 10.9 (17.5) 0.11* 0.7 (0.5, 1.0) 0.014
200–300 67 12.0 (14.8) 0.5 (0.3, 0.8)
> 300 23 7.3 (12.6) 0.2 (0.1, 0.6)
Trend per 100 people (95% CI) 0.8 (0.7, 1.0) 0.008 0.6 (0.4, 0.9) 0.003
Spearmann’s correlation coefficient –0.11 0.04
Percentage of total points
achieved in diabetes domain
> 99 232 12.0 (17.1) 1.0 (ref. cat.)
98–99 51 10.1 (14.2) 0.382* 1.2 (0.7, 2.1) 0.53
97–98 24 11.2 (15.9) 0.9 (0.6, 1.5)
< 97 57 9.1 (19.4) 1.2 (0.8, 1.7)
Trend per 1% reduction (95% CI) 1.0 (0.9, 1.1) 0.955 1.1 (0.9,1.2) 0.398
Spearmann’s correlation coefficient 0.069 0.186
Total QOF pay per list
1 91 13.1 (16.6) 1.0 (ref. cat.)
2 91 10.6 (17.5) 0.665* 0.9 (0.6, 1.2) 0.708
3 91 11.2 (17.0) 1.0 (0.7, 1.4)
4 91 10.1 (15.6) 0.8 (0.6, 1.2)
Trend per increasing quartile (95% CI) 1.0 (0.9, 1.0) 0.325 1.0 (0.8, 1.1) 0.467
Spearmann’s correlation coefficient –0.04 0.437
*Kruskal–Wallis test.
Ratio of geometric mean. Increase in geometric mean prevalence per unit increase in variable. Adjusted for list size, income score,
proportion > 65 years and proportion with HbA1c < 7.4% (57 mmol ⁄mol).
P-value from linear regression.
DN, diabetic nephropathy; IQR, interquartile range; QOF, Quality and Outcomes Framework; ref. cat., reference category.
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were, firstly, that the diabetes prevalence rates appear
comparable with the rest of the United Kingdom at 3.1% in
2005–2006. When corrected for the ages excluded from the
diabetes registers, thefigure rose to4.0%. Incomparisonwith the
slowly increasing prevalence of diabetes in adults, the
documented prevalence of nephropathy grew significantly in
absolute numbers, with a 55% increase from 2004 through to
2008. The prevalence (per diabetes register) increased from
11.5% in 2004–2005 to 15.1% in 2006–2007, reflecting the
growth in the denominator of registered diabetes patients.
In contrast to other studies, the QOF-calculated diabetic
nephropathy prevalence in 2007–2008 is considerably lower
than expected (15%). It is likely that this still reflects incomplete
testing of the at-risk population despite the median 82%
albumin-creatinine ratio testing rate. Compared with other
parts of the United Kingdom, primary care in Northern Ireland
has the highest achievement of QOF screening and treatment
targets for cardiovascular disease and diabetes care [21]. The
limitations of the QOF must also be considered. Firstly, the
natural history of nephropathy is such that onset usually occurs
after 5–10 years of diabetes onset. If, after the QOF, general
practitioners were screening for and diagnosing more diabetes
(earlier than they did hitherto), the complication rate ascertained
in the first years of the scheme may be lower. In addition, using
the presence of microalbuminuria or proteinuria as a method of
identifying patients with diabetic nephropathy will miss those
diabetic patients with ischaemic nephropathy in whom there is
often a normal albumin-creatinine ratio but reduced renal
function.
Secondly, United Kingdom guidelines for establishing
diagnosis based on albumin–creatinine ratio are in place and
recommend repeat albumin-creatinine ratio sampling for results
in the microalbuminuria range [9]. Confirmation of diagnosis
could not be verified in this study, which relies on accurate
general practitioner reporting of abnormal results. There may be
patients who have one abnormal test and are not coded as
nephropathic until confirmation. Future research should try and
establish the positive predictive values for albumin-creatinine
ratios across the range of results, as repeated tests may delay
diagnosis and treatment for some patients.
Using crude prevalence to compare practices obscures the fact
that we cannot identify which patients have died each year and
Table 2 The association between practice level diabetic nephropathy specific Quality and Outcomes Framework (QOF) achievement and diabetic
nephropathy prevalence
Practice characteristic
Number of
practices
Median prevalence
DN (IQR) P
Adjusted ratio of mean
prevalence (95% CI) P
ACR testing rates (%)
< 70 73 16.4 (20.0) 1.0 (ref. cat.)
70–80 80 11.5 (14.7) < 0.01* 0.6 (0.4, 0.9) 0.001
80–90 143 10.3 (16.7) 0.7 (0.5, 0.9)
> 90 68 7.0 (16.1) 0.5 (0.3, 0.7)
Trend per 10% increase (95% CI) 0.8 (0.7, 0.9) < 0.01 0.8 (0.7, 0.9) < 0.01
Spearman’s correlation coefficient –0.18 0.001
ACR exception rates (%)
0–2.8 121 12.0 (19.2) 1.0 (ref. cat.)
2.8–5.9 123 10.9 (15.4) 0.330* 0.9 (0.7, 1.1) 0.335
> 5.9 120 10.2 (15.7) 0.8 (0.6, 1.1)
Trend per tertile increase (95% CI) 0.9 (0.8, 1.1) 0.209 0.9 (0.8, 1.0) 0.156
Spearman’s correlation coefficient –0.07 0.185
RAAS uptake in microalbuminuria (%)
< 70 58 9.2 (32.3) 1.0 (ref. cat.)
70–80 72 15.2 (15.8) < 0.01* 1.3 (0.9, 1.8) < 0.01
80–90 95 16.4 (13.8) 1.6 (1.2, 2.3)
> 90 135 7.1 (9.9) 0.5 (0.4, 0.7)
Trend per 10% increase (95% CI) 0.8 (0.7, 0.9) < 0.01 0.8 (0.7, 0.9) < 0.01
Spearman’s correlation coefficient –0.24 < 0.01
RAAS exception rates in DN (%)
0 200 7.9 (12.2) 1.0 (ref. cat.)
4.3 39 25.5 (20.5) < 0.01* 4.5 (3.2, 6.4) < 0.01
> 4.3 121 14.0 (17.5) 2.0 (1.6, 2.5)
Trend per tertile increase (95% CI) 1.4 (1.2, 1.6) < 0.01 1.4 (1.3, 1.6) < 0.01
Spearman’s correlation coefficient 0.29 < 0.01
*Kruskal–Wallis test.
Adjusted ratio of geometric mean. Model adjusted for list size, income score, proportion > 65 years and proportion with HbA1c < 7.4%
(57 mmol ⁄mol).
P-value from linear regression.
ACR, albumin–creatinine ratio; DN, diabetic nephropathy; IQR, interquartile range; RAAS, renin–angiotensin–aldosterone system; ref. cat.,
reference category.
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which are incident cases. It would be more informative if QOF
registers facilitated an analysis of numbers being annually added
and removed. Practice management may also change over
relatively short periods as a result of retirements and new
appointments, with patients perhaps opting to attend certain
practitioners with special interests in diabetes.
There is maximum variation in the prevalence of diabetic
nephropathy at general practice level (see also Supporting
Information, Appendix S1). After adjusting for factors specific
to the practice, such as age distribution, deprivation, practice size
and diabetes control, the features that most explain these
variations are the number of diabetic patients attending the
practice, practice achievement in screening for albuminuria and
subsequent management. An important finding from this study is
that, in practices with more diabetic patients, the prevalence of
diabetic nephropathy tends to be lower. One hypothesis is that,
amongst practices with relatively fewer cases of diabetes (smaller
case registers), those with more severe disease (i.e. with diabetic
nephropathy) areover-represented.Practiceswith larger diabetes
registers may have more of their patients attending hospital
diabetes clinics and therefore whose diabetic nephropathy status
is inadvertently missed off or poorly recorded in the general
practice registers. Alternatively, those practices may screen for
diabetes more and therefore pick up early cases with a shorter
duration.
Does a greater volume of diabetic patients reduce the chances
of picking up complications or are the practices with larger
registers better at screening and treating diabetes and thus
preventing complications? It may be simply that financial
incentives have resulted in more diabetes patients being
screened and less complex cases detected. Previous studies on
cardiovascular disease found little relationship between caseload
and quality of care [22]. Another study assessing the prevalence
of diabetes mellitus found, as in this study, that smaller practices
have a higher prevalence of nephropathy [23].
Eighty per cent of practices tested > 70% of their diabetic
patients for albumin-creatinine ratio, similar to other studies of
QOF achievement. One English study documented that the
albumin-creatinine ratio testing rate increased to 77% from 7%
in 2004 pre-QOF [24]. Another study conducted in Northern
Ireland before the QOF found albumin-creatinine ratio testing
rates to be 41% [25].
Practices with greater documented use of renin-aldosterone-
angiotensin system blockade in diabetic nephropathy had lower
recorded prevalence rates, but this relationship was not linear.
Mean adjusted prevalence rates were lowest in those practices
recording > 90% achievement in blockade in indicated patients,
after initially increasing with moreusage of thesedrugs. This may
reflect selective use in what practitioners deem to be a higher risk
of diabetic nephropathy, or possibly practices able to achieve
more than 90% uptake of renin-angiotensin-aldosterone system
blockade may have had good screening and treatment measures
in place before the introduction of the QOF.
Exception reporting for albumin-creatinine ratio testing did
not correlate with recorded diabetic nephropathy prevalence;
however, exceptions for the use of renin-angiotensin-aldosterone
system blockade in diabetic nephropathy patients correlated
positively (r = 0.29, P < 0.01). Previously, reports correlating
high levels of exception reporting and performance in the QOF
raised fears about ‘gaming’—to increase practice achievement
and income [26]—but a further larger study found little evidence
of this [27]. Here, practices with the highest exceptions (> 4.3%)
had twice the prevalence rates of those practices with no
exception reporting. Perhaps these practices have a greater
number of patients with co-morbidities and are more susceptible
to exception reporting.
Better-organizedpractices aremore likely toachieve glycaemic
control [27]. In this study, the weighted mean total income from
the QOF was taken as a measure with which to compare how
practices performed in all aspects of the QOF, both in clinical
and organizational domains. Here, there was neither a
significant correlation between increasing QOF income nor
between overall diabetes achievement and recorded diabetic
nephropathy prevalence. It is suggested that a practices’ overall
organizational response to the QOF had no effect on its ability to
diagnose and register nephropathy and that the general quality of
diabetes care had no bearing on current nephropathy prevalence.
General diabetes care has been shown to have been improving
prior to the onset of the QOF, with the financial incentives having
little impact in the longer term [28]. A more prolonged analysis
taking into account the length of time usually required to develop
diabetic nephropathy is needed to further explore this point.
In conclusion, registered diabetic nephropathy prevalence as
calculated from the QOF initially increased to a stable level, but
remains less than in formal population-based studies. Very large
variation in diabetic nephropathy prevalence remains
throughout this period and it is associated with diabetes
registry size, screening and treatment practices and suggests
that understanding this variation may help practices target
diabetic nephropathy patients.
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